← FDA DRUG APPROVALS

FDA NDA · NDA204369

STIVARGA

Sponsor: BAYER HEALTHCARE PHARMS

APPLICATION
NDA204369
TYPE
NDA
ORIGINAL APPROVAL
2013-02-25
LATEST ACTION
2013-02-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

STIVARGAPrescription
REGORAFENIB 40MG · TABLET · ORAL

Approval history

2013-02-25Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →